Skip to content
  • Who We Are
    • Who We Are

      We are a collaborative fund dedicated to ending six neglected tropical diseases that affect more than 1.4 billion people.

      The Board
      The Staff
      Partners
      Anchor Investors
  • What We Do
    • What We Do

      We efficiently put drug donations and private capital to work in support of country-led NTD programs that are innovative, integrated, cost-effective, and sustainable.

      Our Story
      Our Impact
      Impact Stories

      THE LEGACY OF Pharmaceutical Partnerships

      Learn how pharmaceutical partnerships are driving the fight against neglected tropical diseases.

      Learn more
  • Support Our Work
    • Support Our Work

      We believe that investing should be a transformative experience that enhances the lives of partners and beneficiaries alike. Support our mission and join us.

      INVEST

      The END Fund is dedicated to fighting the six most prevalent neglected tropical diseases, which affect 1.495 billion people globally.

      Annual reports

      Explore our annual reports and learn about the END Fund’s impact.

      Watch

      How the END Fund will end neglected tropical diseases.

  • Our Focus
    • We focus on the six most prevalent NTDs that have proven cost-effective interventions: river blindness, lymphatic filariasis, trachoma, intestinal worms, schistosomiasis, and visceral leishmaniasis.

      Intestinal Worms

      Intestinal worms (also known as soil-transmitted helminths) cause malnutrition, anemia, and poor physical and mental growth.

      River Blindness

      River blindness (also known as onchocerciasis) is an eye and skin infection caused by parasitic worms that leads to intense itching and vision loss.

      Schistosomiasis

      Schistosomiasis (also known as bilharzia or snail fever) is a chronic disease caused by parasitic worms that live in freshwater snails.

      Lymphatic Filariasis

      Lymphatic filariasis (also known as elephantiasis) is a mosquito-borne disease that causes disfigurement and longterm disability.

      Trachoma

      Trachoma is a bacterial infection of the eye that can cause irreversible blindness. It is the leading cause of blindness due to infection worldwide.

      Visceral Leishmaniasis

      Visceral leishmaniasis (also known as kala-azar) is a life-threatening disease caused by leishmania parasites, transmitted by female sandflies.

  • Our Funds
    • OUR FUNDS

      The END Fund manages a portfolio of programmatic funds to advance our vision to ensure that people at risk of neglected tropical diseases have the opportunity to live healthy and prosperous lives.

      FLAGSHIP FUND

      To ensure the everyone has access to treatment to live healthy lives.

      DEWORMING INNOVATION FUND

      To accelerate sustained improvements to the overall health and wellbeing of communities by rewriting the disease elimination playbook for parasitic worm infections.

      REACHING THE LAST MILE FUND

      To fast track the effort to eliminate river blindness and lymphatic filariasis.

      ARISE Fund

      To strengthen national and community leadership by co-financing programs with governments and improving efficiency and cost-effectiveness.

      Our Approach
Donate
Donate

✕

Search

Search The End Fund

Annual Report, Report
ARISE Fund, Deworming Innovation Fund, Flagship Fund, Intestinal Worms, Lymphatic Filariasis, Onchocerciasis, Reaching The Last Mile Fund, River Blindness, Schistosomiasis, Trachoma, Visceral Leishmaniasis

2017 Annual Report

March 31, 2018

In 2017, the END Fund treated over 97 million people for NTDs. That included 2,915 surgeries, 160 million treatments distributed, and 344,324 health workers trained. All these efforts equated to a value of over $119 million in treatments for NTD patients. 


Download PDF

Share This Article

Related Stories

Ending neglected diseases within climate resilient health systems

Read More

The road to elimination: The END Fund’s latest Annual Report

Read More

Reaching the last mile: Eliminating onchocerciasis and lymphatic filariasis

Read More
The End Fund

USA: 2 Park Avenue
, 28th Floor
, New York, NY, 10016 phone: +1 646-690-9775


UK: 495 Green Lanes, Palmer Green London, N13 4BS

Kenya: P.O. Box 10752 – 00100, Nairobi. 



[email protected]

The END Fund Inc. is a 501(c)(3), tax-exempt charitable organization registered in the United States (EIN 27-3941186). The END Fund is a company limited by guarantee registered in England and Wales (company number 6350698) and a UK registered charity (number 1122574). The END Fund Kenya is a a non-governmental organization registered in the Republic of Kenya as NGO-POFQMD.

Careers

–

Privacy Policy

–

State Non-Profit Disclosures

–

US Gift Acceptance Policy

–

UK Gift Acceptance Policy

–

Annual Reports and Financial Statements

–

Contact Us

  • LinkedIn
  • Instagram
  • YouTube
  • Facebook
Subscribe to Newsletter
Crafted by Cornershop Creative

© 2024 The End Fund All Rights Reserved